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Mutations in SCARF2 Are Responsible
for Van Den Ende-Gupta Syndrome
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Van Den Ende-Gupta syndrome (VDEGS) is an extremely rare autosomal-recessive disorder characterized by distinctive craniofacial
features, which include blepharophimosis, malar and/or maxillary hypoplasia, a narrow and beaked nose, and an everted lower lip.
Other features are arachnodactyly, camptodactyly, peculiar skeletal abnormalities, and normal development and intelligence. We
presentmolecular data on four VDEGS patients from three consanguineous Qatari families belonging to the same highly inbred Bedouin
tribe. The patients were genotyped with SNPmicroarrays, and a 2.4Mb homozygous region was found on chromosome 22q11 in an area
overlapping the DiGeorge critical region. This region contained 44 genes, including SCARF2, a gene that is expressed during develop-
ment in a number of mouse tissues relevant to the symptoms described above. Sanger sequencing identified a missense change,
c.773G>A (p.C258Y), in exon 4 in the two closely related patients and a 2 bp deletion in exon 8, c.1328_1329delTG (p.V443DfsX83),
in two unrelated individuals. In parallel with the candidate gene approach, complete exome sequencing was used to confirm that
SCARF2 was the gene responsible for VDEGS. SCARF2 contains putative epidermal growth factor-like domains in its extracellular
domain, alongwith a number of positively charged residues in its intracellular domain, indicating that it may be involved in intracellular
signaling. However, the function of SCARF2 has not been characterized, and this study reports that phenotypic effects can be associated
with defects in the scavenger receptor F family of genes.Van Den Ende-Gupta syndrome (VDEGS; MIM 600920) is
an extremely rare autosomal-recessive disorder character-
ized by distinctive craniofacial and skeletal manifestations.
It was first delineated by van den Ende et al. and Gupta
et al.1,2 To date, only 14 patients from nine families have
been described.1–7 Inheritance is likely autosomal reces-
sive, which is supported by consanguinity of affected
matings, the recurrence of the disorder among the
offspring of unaffected couples, and equal sex involve-
ment.2,7 It is characterized by craniofacial abnormalities
that include blepharophimosis, a flat and wide nasal
bridge, malar and/or maxillary hypoplasia, prominent
ears, a narrow and beaked nose, an everted lower lip,
palatal abnormalities, and down-slanting eyes. Skeletal
abnormalities include camptodactyly, arachnodactyly,
long thumbs, and hallux valgus. Patients can have flexion
contractures5 and skeletal findings, such as slender ribs,
hooked clavicles, and bowed long bones.1–4,6,8 Respiratory
problems due to laryngeal abnormalities have also been
described in some patients.4 Two patients have also been
reported to have enlarged cerebella.7
The case for clinical heterogeneity in VDEGS has been
made.5 One mother had affected children with two
different nonrelated partners. The authors postulated
that in this pedigree, VDEGS was inherited in a dominant
manner, possibly as a result of gonadal mosaicism.
In this paper, we are reporting on four patients. The
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The Americskeletal features consistent with VDEGS, as well as some
previously unrecognized clinical findings. Patient 1 pre-
sented with scaphocephaly, blepharophimosis, a beaked
nose, and maxillary hypoplasia. Her mouth was small,
with an everted lower lip. She also had a high-arched and
narrow palate. Both ears were posteriorly rotated, with
folded helix and a small lobule. Upper limbs showed bilat-
eral contracture of elbow joints and camptodactyly of the
second to fifth fingers in both hands with long tapering
fingers. There were long first toes and partial 2-3 skin
syndactyly. Skeletal survey showed abnormal development
of the proximal radius, with evidence of radioulnar sublux-
ation, and no clear demonstration of osseous fusion. Her
cousin, patient 2, had scaphocephaly, blepharophimosis,
a beaked nose, maxillary hypoplasia, and a small mouth
with an everted lower lip and limited opening. He also
had a high-arched and narrow palate, abnormal teeth,
and micrognathia. Both ears were posteriorly rotated,
with folded helix and small lobule. Upper limbs showed
bilateral contracture of elbow joints and camptodactyly
of the second to fifth fingers in both hands with long
tapering fingers. There were long first toes and partial 2-3
skin syndactyly. A distinguishing finding from what was
seen in patient 1 was a sacral dimple. Patient 3 had similar
features but also showed hypoplastic scapulae, clavicles,
and ribs. Patient 4 showed similar features, but renal ultra-
sound showed bilateral renal pelvis dilatation.9 All patients
were the products of consanguineous marriages.1, Canada; 2Section of Clinical andMetabolic Genetics, Department of Pedi-
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Figure 1. Pedigrees of Patients Affected with VDEGS
(A–C) The consanguinity and relationship for both patients 1 and 2 are shown in (A). The two patients are related. Information for
patient 3 is shown in (B) and for patient 4 in (C). Black denotes patients affected with VDEGS.The camptodactyly and facial features in these patients
initially suggested thediagnosis of Teebi Shaltout syndrome
(TSS; MIM 272950). TSS is another extremely rare auto-
somal-recessive syndrome, with only five cases (including
three spontaneously aborted fetuses) from two families re-
ported to date.10,11 TSS has historically presented as
a syndrome of camptodactyly, kidney anomalies, a caudal
appendage, and distinctive craniofacial anomalies. The
craniofacial anomalies in TSS include scaphocephaly with
prominent occiput and bitemporal depression, abnormal
hair, hypertelorism, ptosis and blepharophimosis ormicro-
phthalmia, a bulbous nose with hypoplastic alae nasi,
a small mouth, and abnormal teeth.10,11 Therefore, TSS
seems to share some phenotypic features with our patients
that have not been, as yet, linked with VDEGS.
In order to identify the genetic defect responsible for
VDEGS, we utilized a homozygosity mapping or candidate
gene approach, as well as a second, whole-exome capture
approach. Analyses were carried out on genomic DNA
from four individuals affected with the disease and
a number of unaffected individuals (Figures 1A–1C). All
individuals were members of the same Bedouin tribe, and
two affected individuals (patients 1 and 2) were directly554 The American Journal of Human Genetics 87, 553–559, Octoberrelated (Figure 1A). This study was performed under
a protocol approved by the Hamad Medical Corporation
for a search for genes in consanguineous families, and
consent was obtained from all participants.
In order to identify a homozygous region, Illumina Hap
550K Duo Infinium chips were used to genotype patients
1, 2, and 3, as well as one control individual, an unaffected
sibling of patient 1. The program PLINK12 with default
settings was used to identify regions of homozygosity that
were shared by the affected individuals but not the control.
A single such segmentof 2.4Mbwas foundonchromosome
22q11, extending between positions 16910984 and
19296457 (hg18 reference coordinates; Figure 2). Patient 1
(0396) was homozygous across a 6.0 Mb interval, contain-
ing 1191 genotyped SNPs, delimited by rs466755 and
rs8141797. Patient 2 (0946) was homozygous across a
4.0Mb interval, containing 783 genotyped SNPs, delimited
by rs2027653 and rs1108101. Patient 3 (0116)washomozy-
gous across a 6.2 Mb interval, containing 1300 genotyped
SNPs, delimited by rs9606661 and rs6003815. Patient 4
was also subsequently genotyped and was found to be
homozygous for a 16.0 Mb region, delimited by
rs2236639 and rs3827342. Interestingly, the haplotypes8, 2010
Figure 2. Homozygosity Mapping Results
Location and region delimiting SNPs of the
2.4 Mb homozygous region on chromosome
22q11 shared by the four VDEGS patients (boxed
area). Blue denotes individual homozygous
regions and haplotype shared by patients 1 and
2, red denotes homozygous region of patient 3,
green denotes the homozygous region of patient
4, and yellow denotes the shared haplotype
within the homozygous regions of patients 3
and 4. Patients 3 and 4 reflect complex levels of
relatedness within the tribal population. Each
patient carries a haplotypically distinct homozy-
gous segment resulting from the most recent
consanguinity. However, within these large
segments, the two patients share a smaller
common haplotype, most likely inherited from
a more distant common ancestor of the parents.in the region shared by the affected patients were not iden-
tical: patients 1 and2 shared a commonhaplotype,whereas
patients 3 and 4 were homozygous for a 1.6 Mb distinct
haplotype block within their individual homozygous
regions (delimited by rs885988 and rs2075277; Figure 2).
This finding suggested the presence of either more than
one founder mutation or a smaller shared haplotype—
undetectable at the current genotyping resolution—within
the candidate region. The region of shared homozygosity
contained a total of 44 annotated genes.
Candidate genes were chosen via PubMed article data-
base searches, as well as by looking at previous studies on
gene expression patterns in the developing mouse fetus.
Initial candidate genes were chosen based on high expres-
sion in the limb buds of developing mice. The coding
regions of DGCR8 (MIM 609030), HIRA (MIM 600237),
MED15 (PCQAP [MIM 607372]), and MRPL40 (NLVCF
[MIM 605089]) were all sequenced, and no causative muta-
tions were found.
The next candidate selected was SCARF2. SCARF2 (SREC-
II) is a member of the scavenger receptor type F family.13 Its
11 exons encode a protein 866 amino acids in length. It
produces a membrane protein with a predicted weight of
91 kDa. The extracellular region contains a number of
putative N-glycosylation sites and putative disulphide
bridge formation sites, as well as seven epidermal growth
factor (EGF)-like domains, as identified by the CXC
XXXXXGXXC signature. As in themouse, the intracellular
region is rich in positively charged amino acids such asThe American Journal of Humlysine and arginine and contains a number
of putative phosphorylation sites, indi-
cating that it may act as an intracellular
signaling protein that may interact with
other proteins within the cytoplasm to
mediate intracellular signaling.13
Expressed sequence tag data reveal
expression of Scarf2 in branchial or pharyn-
geal arch and mandibular, maxillary, and
urogenital ridge tissues on the tenth embry-
onic day.14 It is also known to be expressedin human endothelial cells, and RNA blot analysis revealed
its expression in human heart, lung, ovary, and placental
tissue.14 Because most of the clinical features of VDEGS
can be explained by failure of proper branchial arch devel-
opment, SCARF2 was an excellent candidate within the
region defined by homozygosity mapping.
Primers were designed, and the coding exons of SCARF2
were sequenced from the genomic DNA of the four
patients and four unaffected relatives. Sanger sequencing
and analysis with Sequencher identified a homozygous
2 bp deletion in exon 8, c.1328_1329delTG
(p.V443DfsX83), in patients 3 and 4 (Figure 3A). These
individuals were not directly related to patients 1 and 2,
and, as previously mentioned, patients 3 and 4 did not
share the same haplotype as the other two affected patients
in the candidate region. The deletion results in a frame-
shift, causing a premature stop codon that should result
in the transcript’s degradation via nonsense-mediated
decay, resulting in absence of the protein.15 If the mRNA
transcript was able to escape degradation, the protein
would lack a large portion of the intracellular region,
which is thought to be involved in intracellular signaling.
A homozygous missense change, c.773G>A (p.C258Y;
Figure 3B), was found in exon 4 of both patients 1 and 2.
Themissensemutation is predicted to eliminate the forma-
tion of the respective disulfide bridge within the putative
EGF-like domain and thus affect the folding of this
domain. This cysteine residue is very highly conserved
and is present even in the zebrafish, whereas surroundingan Genetics 87, 553–559, October 8, 2010 555
Figure 3. Sequencing and Exome Capture Results
(A) Presence and effect of c.1328_1329delTG mutation.
(B) Presence and effect of c.773G>A mutation.
(C) Conservation of residues near 773G>A (p.C258Y) mutation. Black denotes residues conserved across all species; gray denotes resi-
dues that are different in at least one species. Asterisk (*) indicates the residue changed by the mutation.
(D) Exome capture and sequencing results in the mother of patient 1. Red ‘‘T’’s indicate deviation from RefSeq sequence (bottom).
Sequencing shows a heterozygous state of the c.773G>A mutation.
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residues are not (Figure 3C). Previous studies have also
shown that mutations in the calcium-binding EGF-like
domain of other proteins may result in the degradation
of those products.16
The presence of these mutations was also confirmed via
restriction endonuclease digestion with AflIII (c.773G>A)
and BtgZ1 (c.1328_1329delTG). The mutations have not
been reported as polymorphisms in the single nucleotide
polymorphism database (dbSNP) or the 1000 Genomes
Databases. We performed Sanger sequencing of the rele-
vant regions in 196 healthy control individuals: 54 Qatar
Bedouin members of the same tribe as the patients, 59
Arab, 11 Iranian, 8 Southwest Asians, and 64 Northern
Europeans. The c.1328_1329delTG mutation was not
found in any of the control samples. However, the
c.773G>A variant was found in heterozygous state in
one unaffected Bedouin. We thus estimate the frequency
of this mutation to be 1/108 in this Bedouin tribe, trans-
lating to at least 1 in 12,000 incidence of the disease. Lastly,
both unaffected siblings of patient 2 available in this study
were homozygous for the reference allele of SCARF2, and
the mothers of patient 2 and patient 4 were heterozygous
for the missense change and the deletion, respectively.
All of the above evidence strongly supports the causative
role of SCARF2 mutations in the VDEGS.
It has been previously shown that whole-exome capture
technology is able to identify disease-causing genes by
sequencing a single or a small number of affected individ-
uals.17–19 For this reason, we chose to utilize thismethod in
parallel to homozygosity mapping and candidate gene
selection. With the SureSelect Human All Exon Kit from
Agilent, we were able to capture and target all coding
exons—about 27.9 Mb total sequence—in the human
genome. Because of a limiting amount of DNA available
from the patients, we proceeded to capture and sequence
the exome of the mother (person 5) of patient 1. Within
the minimal candidate region, we expected to identify
a number of heterozygous variants, which would then be
used for validation—as homozygotes—in the patients.
Using two lanes of 76 base reads of Illumina GAIIx
sequencing, we obtained>4 Gb of quality-controlled reads
that could be mapped to the genome. This was sufficient
for an average 503 coverage of the exome. We used the
Samtools20,21 software and SIFT22 functional annotation
to identify potentially damaging SNPs within the region.
Within our 44 candidate genes, we identified only two
nonsynonymous variants, chr22:18156380A>G (hg18
coordinates) in GNB1L (MIM 610778) and
chr22:19115386C>T in SCARF2 (Figure 3D), which were
not annotated as polymorphisms in dbSNP or the 1000
Genomes Database. The SCARF2 mutation was already
shown to be homozygous in patients 1 and 2, and, along
with the homozygous 2 bp deletion present in patients 3
and 4, this constitutes strong evidence that SCARF2 is
the gene mutated in VDEGS. We followed up the putative
involvement ofGNB1L by sequencing this gene in our four
patients. The GNB1L variant was found to be homozygousThe Americin patients 1 and 2, indicating that both the GNB1L and
SCARF2 variants are present on the same ancestral haplo-
type. However, neither patient 3 nor 4 carried this variant
or any other mutation within GNB1L. Although it is
possible that the GNB1L mutation contributes to the
phenotypes observed in patients 1 and 2, its absence in
patients 3 and 4 argues against its general involvement
in VDEGS. Hence, we conclude that SCARF2 is the gene
mutated in VDEGS patients and is primarily responsible
for the VDEGS phenotype.
The exome capture and next-generation sequencing
results illustrate two points. First, this approach can indeed
be used to narrow down sets of candidate genes and iden-
tify mutations, even in a heterozygote state. Second, the
high-throughput sequencing results can also be used to
exclude the remainder of candidate genes within the
region and provide additional evidence for the causative
nature of detected mutations.
Little is known about SCARF2. It is highly homologous
to SCARF1 (MIM 607873), with very similar extracellular
domains containing multiple EGF-like repeats, but their
intracellular domains are significantly different, indicating
that they may be involved in different signaling pathways
within the cell.13 Unlike SCARF1, SCARF2 has little ability
to internalize modified low-density lipoprotein (LDL),
such as acetylated and oxidized LDLs, although it has
been demonstrated that SCARF2 expression is upregulated
in the presence of oxidized LDLs.23 The two related
proteins are thought to interact via a heterophilic trans
interaction through their extracellular domains.13
Evidence of a physiological relevance to the interaction
between SCARF1 and SCARF2 comes from a study that
demonstrated that mouse fibroblast cells showed slightly
increased aggregation when either SCARF1 or SCARF2
was overexpressed on their cell surfaces and that aggrega-
tion became significantly increased when cells overex-
pressing SCARF1 were mixed with those expressing
SCARF2. This aggregation was suppressed when modified
LDLs were present.
VDEGS maps to the 22q11.2 region that contains the
critical region of the velo-cardio-facial/DiGeorge syndrome
(MIM 18840). Like VDEGS, DiGeorge syndrome is also
characterized by craniofacial abnormalities such as micro-
gnathia and a bulbous nose, but with the addition of
cardiac defects, thyroid problems, and velopharyngeal
insufficiency.24 A majority of patients are hemizygous for
a 3 Mb region of chromosome 22 or a smaller 1.5 Mb
nested deletion. The major phenotypic effect in DiGeorge
syndrome has been attributed to the deficiency in TBX1
(MIM 602054),24 but the exact roles played by other genes
remain elusive. It is possible that deficiency of SCARF2may
contribute to some of the atypical phenotypes, particularly
those associated with larger deletions in patients with
DiGeorge syndrome.
This study elucidates the importance of SCARF2, a rela-
tively uncharacterized gene. It appears to play an impor-
tant role in the proper development of a number of organs.an Journal of Human Genetics 87, 553–559, October 8, 2010 557
SCARF2’s precise role requires further study, and the crea-
tion of a knockout mouse model is currently under way.Acknowledgments
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